Market Research Logo

Mesoblast Limited - Product Pipeline Review - 2015

Mesoblast Limited Snapshot
Mesoblast Limited Overview
Key Information
Key Facts
Mesoblast Limited - Research and Development Overview
Key Therapeutic Areas
Mesoblast Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Mesoblast Limited - Pipeline Products Glance
Mesoblast Limited - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Mesoblast Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Mesoblast Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Mesoblast Limited - Drug Profiles
MPC-06ID
Product Description
Mechanism of Action
R&D Progress
MPC-150IM
Product Description
Mechanism of Action
R&D Progress
MPC-25Osteo
Product Description
Mechanism of Action
R&D Progress
MPC-CBE
Product Description
Mechanism of Action
R&D Progress
remestemcel-L
Product Description
Mechanism of Action
R&D Progress
MPC-25IC
Product Description
Mechanism of Action
R&D Progress
MPC-300IV
Product Description
Mechanism of Action
R&D Progress
MSBCAR-001
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Parkinson Disease and Ishemia Stroke
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Cardiovascular Diseases
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology
Product Description
Mechanism of Action
R&D Progress
Mesoblast Limited - Pipeline Analysis
Mesoblast Limited - Pipeline Products by Target
Mesoblast Limited - Pipeline Products by Route of Administration
Mesoblast Limited - Pipeline Products by Molecule Type
Mesoblast Limited - Pipeline Products by Mechanism of Action
Mesoblast Limited - Recent Pipeline Updates
Mesoblast Limited - Dormant Projects
Mesoblast Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Mesoblast Limited, Key Information
Mesoblast Limited, Key Facts
Mesoblast Limited - Pipeline by Indication, 2015
Mesoblast Limited - Pipeline by Stage of Development, 2015
Mesoblast Limited - Monotherapy Products in Pipeline, 2015
Mesoblast Limited - Phase III, 2015
Mesoblast Limited - Phase II, 2015
Mesoblast Limited - Preclinical, 2015
Mesoblast Limited - Pipeline by Target, 2015
Mesoblast Limited - Pipeline by Route of Administration, 2015
Mesoblast Limited - Pipeline by Molecule Type, 2015
Mesoblast Limited - Pipeline Products by Mechanism of Action, 2015
Mesoblast Limited - Recent Pipeline Updates, 2015
Mesoblast Limited - Dormant Developmental Projects,2015
Mesoblast Limited, Subsidiaries
List of Figures
Mesoblast Limited - Pipeline by Top 10 Indication, 2015
Mesoblast Limited - Pipeline by Stage of Development, 2015
Mesoblast Limited - Monotherapy Products in Pipeline, 2015
Mesoblast Limited - Pipeline by Top 10 Target, 2015
Mesoblast Limited - Pipeline by Top 10 Route of Administration, 2015
Mesoblast Limited - Pipeline by Top 10 Molecule Type, 2015
Mesoblast Limited - Pipeline Products by Top 10 Mechanism of Action, 2015

Mesoblast Limited - Product Pipeline Review - 2015

Summary


Global Markets Direct’s, ‘Mesoblast Limited - Product Pipeline Review - 2015’, provides an overview of the Mesoblast Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mesoblast Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mesoblast Limited’s pipeline products
Reasons to buy
  • Evaluate Mesoblast Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mesoblast Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mesoblast Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;